Surfing the MASH Tsunami

<p>Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL</p>

S6.13.3 - Major Issues in MASH-ville: US Government Chaos and Scanning Market Dynamism

Send us a text This discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger Green) Roger drives this conversation, focusing on two very different, yet very important issues: the first is the increasing dynamism of the in-office scanning market, with leader Echosens developing new products and services, whi...

09-11
37:13

S6.13.2 - Newsmakers: Updating Our Approach to Screening for Advanced Liver Disease

Send us a text Last month, The Lancet posted online an article from Stine Johansen, Fredrik Åberg, Emmanuel Tsochatzis and Aleksander Krag, titled "Screening for Advanced Liver Disease." The article aims to update the Wilson and Jungner criteria, initially developed in 1960, to address modern needs and issues. In this conversation, Professor Krag and Dr. Johansen join Roger Green to discuss their article. There are many nuances and high points to cover in this thoughtful, fairly lengthy...

09-09
20:19

S6.13.1 - Major Issues in MASH-ville: Developing a More Integrated Approach to MASH Patient Management

Send us a text This discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger Green) Louise drives this conversation based on two related issues she sees emerging: (i) increasing opportunities for motivated patients to manage their own health and (ii) managing the total patient in an environment where people m...

09-09
19:48

S6.13 - Locating MASH patients, Population Screening for Advanced Disease, Impact of Washington on Americans' Health

Send us a text 00:00:00 - Surf's Up: Season 6 Episode 13 Louise Campbell, Jörn Schattenberg and Roger Green continue their discussion of some major issues from earlier this year, while co-authors Aleksander Krag and Stine Johanset join Roger to discuss their recent publication in The Lancet, titled "Screening for Advanced Liver Disease." 00:04:45 - Major Issues of the First Six Months: Integrated Patient Management Louise drives this conversation based on two related issues she se...

09-05
01:13:53

S6.12.3 - After the Semaglutide Approval: What Next For MASH Therapy?

Send us a text Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation centers on the roles that new technologies and an expanded APP population will play in MASLD and MASH management in the US, and concludes by exploring how care might look different 12 months from now, and then in subsequent years. As panelists identify some of the changes...

09-02
21:39

S6.12.2 - After the Semaglutide Approval: Expanding MASH Awareness Will Change Medical Practices

Send us a text Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on how the US healthcare system must adapt to handle the growing number of MASH and MASLD patients who might seek treatment, given likely increases in publicity and education. The conversation starts with a focus on the implications of semaglutide approval for hepatolog...

08-31
22:58

S6.12.1 - After the Semaglutide Approval: Impact on Patients and Pharmacotherapy

Send us a text Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and ways that having two drugs with different modes of action will change pharmacotherapy choices. This conversation starts with the group describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs ...

08-31
24:35

6.12 - A Second US Drug Approval! What Semaglutide's Success Portends For MASLD Care in the US

Send us a text 00:00:00 - Surf's Up, Season 6, Episode 12 This week's episode is a special three-part roundtable on the implications of the FDA's recent approval of semaglutide. Naim Alkhouri, Manal Abdelmalek, Scott Isaacs and Zobair Younossi join Roger Green in a discussion that focuses less on specifics of pharmacotherapy and more on how having two drugs available will change MASH management in the US. 00:08:45 - Part I: How Will The Semaglutide Approval Affect Patient Treatment and Pharma...

08-29
01:04:23

6.11.3 - Expert: Emily Andaya Asks Why There Is No "L" In the (Multi-Meatbolic) CKM Initiative

Send us a text This week's expert interview is with Dr. Emily Andaya, Medical Director of the Cardiovascular Program at Major Health Partners of Shelbyville, IN. She joins Louise Campbell and Roger Green to discuss the American Heart Assocation's CKM initiative, why she believe it should be titled "CKLM" for liver, and how including liver in the CKM scoring system would make it stronger and provide a more robust tool to help improve patients' health. Emily begins by discussing her atten...

08-17
41:03

6.11.2 - Multi-Metabolic Week Part II: Benefits of the Multi-Metabolic Approach

Send us a text Multi-Metabolic Week focuses on the idea that MASLD and MASH are elements in a systemic set of Multi-Metabolic issues. This conversation is the second of two looking at the concept of the "Multi-Metabolic Clinic," a clinic that treats the entire spectrum of multi-metabolic diseases. This conversation starts by focusing on how the two clinics train other physicians and practices on multi-metabolic issues. The EDOM clinic in Spain is certified to provide nutritional training to o...

08-17
43:59

6.11.1 - Multi-Metabolic Week Part I: Role of MASLD In Multi-Metabolic Clinics

Send us a text Multi-Metabolic Week focuses on the idea that MASLD and MASH are elements in a systemic set of Multi-Metabolic issues. This conversation is the first of two looking at the concept of the "Multi-Metabolic Clinic," a clinic that treats the entire spectrum of multi-metabolic diseases. The core of this episode starts during the weekly groundbreaker exercise, during which our guests began to describe the path that brought them from single-disease specialization to the broader ...

08-16
37:34

6.11 - Multi-Metabolic Practices Integrate MASLD with Other Non-Communicable Diseases

Send us a text 00:00:00 - Surf's Up: Season 6, Episode 11 This week, we modify our usual episode structure to focus on multi-metabolic practices and constructs. The multi-metabolic practices covered this week are run by non-hepatologists who have chosen to focus on the liver in a broader cardiometabolic context. They include two practices discussed during a two-part roundtable, one run by US gastroenterologist Dr. Karen Jerome-Zapadka and the EDOM practice in Spain, run by endocrinologi...

08-15
01:49:45

6.10.3 - Expert: Tim Jobson on Using Basic Data and Analytics to Identify At-Risk Patients

Send us a text This week's expert is Tim Jobson, Medical Director of Predictive Health Intelligence, a UK-based consultancy. Tim joins Louise Campbell and Roger Green to share an update on PHI's Somerset UK project and other activities. The Somerset pilot was designed to help the NHS identify untreated patients at high risk for liver disease and bring them to the office for screening. Tim describes hepatoSIGHT, a tool that "allows clinicians to get their hands on the data and to find pa...

08-10
37:16

6.10.2 - Newsmakers: LiverRight Launches America's First Virtual Hepatology Clinic

Send us a text Roger Green talks with LiverRight CEO Brandon Tudor and Chief Medical Officer Alexander Lalos about the launch of LiverRight, America's first virtual hepatology clinic, which has recently begun treating patients. Brandon starts the conversation by telling the story of how he and his partner, Pete Celano, started LiverRight: they saw liver disease as a growing disease in a medical system that was ill-equipped to provide front-line care. When the two men "secret shopped" getting ...

08-09
30:49

6.10.1 - FIrst Six Months, Part I: The Promise of Proteomics For Developing Individualized Treatment Plans

Send us a text This conversation is the first segment of SurfingMASH’s July discussion of key events from the first six months of 2025. Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green each chose one topic of personal interest. Today, Jörn Schattenberg discusses two recent papers that demonstrate differences in how individual patients respond to different proteomic tests and what this can mean for individualized treatment plans. Jörn begins by citing Modulation of megab...

08-09
27:36

6.10 - New Approaches to Patient Care: NIT-driven drug choices, Virtual Clinics, Large-Scale Screening

Send us a text 00:00 - Surf's Up 6.10.1 This conversation covers three topics. Jörn Schattenberg discusses two papers that suggest an exciting role NITs might play in future prescribing decisions, two executives from LiverRight describe the U.S.'s first virtual liver clinic, and Tom Jobson of Predictive Health Intelligence updates us on how simple analyses of large data bases can identify and motivate high-risk liver patients to visit their doctors. 00:17:30 - Roundtable: NITs might hel...

08-08
01:32:25

6.9.3 - Expert: Naim Alkhouri Discusses His Long Friendship with Stephen Harrison and His New Role at Summit Clinical Research

Send us a text Hepatologist and hepatology key opinion leader Naim Alkhouri joins Roger Green to remember his longstanding relationship with Stephen Harrison, announce his new role as Chief Academic Officer at Summit Clinical Research and share how, in this role, he will have exciting new avenues make an impact on many elements of MASH drug development and patient care. The conversation can be divided into two sections. In the first, Naim recounts his relationship with Stephen Harrison,...

08-06
29:12

6.9.2 - Newsmaker: Fatty Liver Alliance President Mike Betel Discusses His 3rd Annual 30-Day Glucose Challenge

Send us a text Fatty Liver Alliance President Mike Betel joins Roger Green to discuss his recent completion of the 3rd Annual Glucose Challenge, an event every July where Mike wears a continuous glucose monitor (CGM) device for a month, conducts food experiments, tracks glucose levels and shares all results with his LinkedIn and FattyLiver.ca friends and followers. The conversation starts with Mike sharing the history of the Glucose Challenge. Over its first three years, it has evolved ...

08-05
39:31

6.9.1 - #SLDThinkTank2025, Part III: Unique Challenge of Nutrition Management and Role Politicians Can Play

Send us a text This conversation is the third and final segment of SurfingMASH’s July discussion of #SLDThinkTank 2025. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include Dr. Kristina Curtis of Applied Behaviour Change, a UK-based consultancy. Louise begins this conversation by highlighting the low level of correct information (and, frequently, high level of passionately-held misinformation) that adults have about diet and her success in improv...

08-05
23:35

6.9 - Complexities of Behavior Change, Devices That Can Help, Future of Clinical Trials and MedEd

Send us a text 00:00:00 - Surf's Up: Episode 6.9 This conversation covers three topics. The first discusses the challenges of behavior change in dietary habits and ways governments can help, the second looks at what one can learn from wearing a CGM for 30 days, and the third celebrates the late Stephen Harrison while looking into the future of clinical trials and medical education. 00:06:12 - Global Think-Tank on SLD Roundtable, Part 3 Behavior consultant Dr. Kristina Curtis joins Jörn ...

08-01
01:17:21

Recommend Channels